Quarterly report (Form 10-Q)
West Pharmaceutical Services 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
West Vantage gross profit decreased by $6.3 million, or 20.8%, for the three months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $0.1 million. West Vantage gross profit margin decreased by 2.8 percentage points for the three months ended September 30, 2026, as compared to the same period in 2025, due to product mix, inflationary pressures on our plant spend, and plant ramp up costs related to our drug handling programs, partially offset by sales price increases.